Gray zone lymphoma (GZL) is a rare hematological malignancy known to usually occur in young men. GZL has features intermediate between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma. This case report describes a 55-years old woman with GZL. Remission was achieved through R-CHOP chemotherapy and adjuvant radiation treatment over 22 months. This case is exemplary for successful management of GZL with R-CHOP chemotherapy.
Introduction
Gray zone lymphoma (GZL) is a distinct type of B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin's lymphoma (HL) [1] . GZL is extremely rare and occur mostly in young men [2] . Herein, we present a case of a middle-aged woman with GZL to add to the scant body of knowledge for this rare disease.
Case Presentation
A 55-years old woman presented with 6 weeks' history of dull aching abdominal and back pain. She also has been experiencing tingling and numbness from her feet all the way up to her navel. She reported multiple episodes of fall due to sudden loss of coordination. Her medical history was significant for rheumatoid arthritis and atrial fibrillation. A computerized tomography (CT) with contrast demonstrated filling defects in the liver and spleen, consistent with lymphoma. Multiple small lymph nodes (LNs). Nonetheless, other hematopoietic cells were moderately reduced in numbers. Iron store was also reduced in amount.
These characteristics are consistent with nodular sclerosis type of Hodgkin's disease.
Combining the LN and BM findings, this neoplasm was classified as gray zone lymphoma. The patient was treated with a regimen known as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Following 22 months of systemic chemotherapy with adjuvant radiation treatment, the gray zone lymphoma eventually went into remission.
Discussion
Our case is exemplary for successful management of gray zone lymphoma (GZL). Our patient had excellent therapeutic outcome to R-CHOP chemotherapy and adjuvant radiation treatment. By reporting this case, we hope to help expanding the knowledge on therapeutic options for GZL. Since the formal identification of GZL by World
Health Organization (WHO) in 2008, definition of this disease is still rapidly evolving [2] . The pathophysiology underlying this disease remains poorly understood due to its recent recognition in the medical community and rarity.
For the same reason, there is no well-established treatment for this malignancy.
However, like our case, some oncologists had good outcome by adding rituximab to standard chemotherapy regimens, such as DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and CHOP, for GZL positive for CD20 [3] . Another chemotherapeutic regiment reported to be effective in GZL is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with rituximab [4] .
